Valuation: BioNTech SE

Capitalization 19.42B 22.83B 18.18B 17.06B 31.42B 2,072B 34.34B 212B 81.87B 974B 85.63B 83.81B 3,541B P/E ratio 2025 *
-23.8x
P/E ratio 2026 * -32.5x
Enterprise value 8.79B 10.34B 8.23B 7.73B 14.23B 938B 15.55B 95.87B 37.07B 441B 38.77B 37.95B 1,603B EV / Sales 2025 *
3.27x
EV / Sales 2026 * 3.45x
Free-Float
86.48%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: BioNTech SE

1 day-1.05%
1 week-2.54%
Current month-9.05%
1 month-9.00%
3 months-3.03%
6 months-11.97%
Current year-17.67%
More quotes
1 week 93.63
Extreme 93.63
97.69
1 month 93.63
Extreme 93.63
104.05
Current year 81.2
Extreme 81.2
129.27
1 year 81.2
Extreme 81.2
129.27
3 years 76.53
Extreme 76.5301
183.64
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO 52 2014-08-31
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 68 2008-06-01
Director/Board Member 64 2017-12-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.05%-2.54%-22.07%-49.58% 22.8B
-3.93%-6.15%+24.59%+96.68% 54.11B
-0.05%+0.19%+168.32%+911.92% 42.02B
-3.02%+0.90%+61.43%+15.98% 39.6B
-0.10%-0.94%+39.94%-36.62% 19.5B
-3.11%-0.55%+82.25%-36.14% 17.76B
-6.67%-6.37%+82.56%+170.86% 14.73B
-1.08%-6.68%-6.96%+385.47% 13.55B
-8.21%-12.48%+114.61% - 13.14B
-1.91%-1.41%+80.25%+791.18% 12.98B
Average -2.91%-1.59%+62.49%+249.97% 25.02B
Weighted average by Cap. -2.64%-1.75%+64.92%+251.87%
See all sector performances

Financials

2025 *2026 *
Net sales 2.69B 3.16B 2.52B 2.36B 4.35B 287B 4.75B 29.3B 11.33B 135B 11.85B 11.6B 490B 2.59B 3.05B 2.43B 2.28B 4.2B 277B 4.59B 28.29B 10.94B 130B 11.44B 11.2B 473B
Net income -877M -1.03B -821M -770M -1.42B -93.55B -1.55B -9.56B -3.7B -43.99B -3.87B -3.78B -160B -530M -623M -496M -465M -857M -56.5B -937M -5.77B -2.23B -26.57B -2.34B -2.29B -96.57B
Net Debt -10.63B -12.49B -9.95B -9.34B -17.2B -1,134B -18.79B -116B -44.8B -533B -46.86B -45.86B -1,938B -10.47B -12.3B -9.79B -9.19B -16.93B -1,116B -18.5B -114B -44.11B -525B -46.14B -45.16B -1,908B
More financial data * Estimated data
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
6,772
More about the company
Date Price Change Volume
25-12-15 93.75 $ -1.12% 947,645
25-12-12 94.81 $ -1.24% 849,047
25-12-11 96.00 $ +0.28% 1,185,056
25-12-10 95.74 $ -0.12% 958,274
25-12-09 95.85 $ -1.47% 1,548,700

Delayed Quote Nasdaq, December 15, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.72EUR
Average target price
118.09EUR
Spread / Average Target
+48.14%
Consensus

Quarterly revenue - Rate of surprise